Skip to main content Back to Top
Advertisement

10/8/2021

Cefotaxime Sodium Injection

Products Affected - Description

    • Claforan injection, Baxter, 1 gram/50 mL, frozen premixed bag, 24 count, NDC 00039-0038-05 - discontinued
    • Claforan injection, Baxter, 2 gram/50 mL, frozen premixed bag, 24 count, NDC 00039-0039-05 - discontinued
    • Cefotaxime Sodium powder for solution for injection, Hikma, 1 gram, vial, 25 count, NDC 00143-9931-25
    • Cefotaxime Sodium powder for solution for injection, Hikma, 10 gram, vial, 1 count, NDC 00143-9935-01
    • Cefotaxime Sodium powder for solution for injection, Hikma, 2 gram, vial, 25 count, NDC 00143-9933-25
    • Cefotaxime Sodium powder for solution for injection, Hikma, 500 mg, vial, 10 count, NDC 00143-9930-10

Reason for the Shortage

    • Hospira has discontinued Claforan. Sanofi-Aventis manufactured Claforan for Hospira and is no longer making the product.
    • Hikma is not currently marketing cefotaxime injection.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Provepharm is temporarily importing cefotaxime 1 gram and 2 gram vials. Product is estimated to be available through Direct Success in late-October 2021.

Alternative Agents & Management

    • FDA is allowing temporary importation of cefotaxime 1 gram and 2 gram vials from Provepharm and its distributor Direct Success. The cefotaxime is supplied by SteriMax from Canada. Customers can contact Direct Success at [email protected] or 1-877-404-3338 to place orders. See https://www.fda.gov/media/152806/download for details.

Updated

Updated October 8, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. Created July 31, 2013 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.